These findings, besides showing reversion of altered malprogramming structures and functions due to adverse prenatal conditions, are in favor of the potential usefulness of the L/G ratio measurement in adulthood as a clinical non-invasive marker of programmed susceptibility to develop obesity-related alterations; furthermore, it also seems to be able to detect the reversion of these disruptions by early life treatment, being more sensitive than leptin or ghrelin alone. The gene discussed is GHRL; the disease is obesity disorder.